These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 15909786)

  • 1. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
    Am J Hosp Palliat Care; 2005; 22(3):228-32. PubMed ID: 15909786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
    J Opioid Manag; 2005; 1(1):36-40. PubMed ID: 17315410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
    Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
    Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fentanyl buccal tablet.
    Messina J; Darwish M; Fine PG
    Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology.
    Mystakidou K; Tsilika E; Tsiatas M; Vlahos L
    Int J Nanomedicine; 2007; 2(1):49-54. PubMed ID: 17722512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Vlahos L; Tsiatas ML
    Drug Deliv; 2006; 13(4):269-76. PubMed ID: 16766468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and clinical differences among transmucosal fentanyl formulations for the treatment of breakthrough cancer pain: a review article.
    Corli O; Roberto A
    Minerva Anestesiol; 2014 Oct; 80(10):1123-34. PubMed ID: 24346227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review.
    Gordon DB
    Oncol Nurs Forum; 2006 Nov; 33(2):257-64. PubMed ID: 16518441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
    Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK
    Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain.
    Rees E
    Int J Palliat Nurs; 2002 Jun; 8(6):304-8. PubMed ID: 12131825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Breakthrough pain frequency in cancer patients and the efficiency of oral transmucosal fentanyl citrate].
    Bilen A; Ali A; Baturay F; Altan A
    Agri; 2010 Jul; 22(3):103-8. PubMed ID: 20865581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing breakthrough pain: a clinical review with three case studies using oral transmucosal fentanyl citrate.
    Rhiner M; Palos G; Termini M
    Clin J Oncol Nurs; 2004 Oct; 8(5):507-12. PubMed ID: 15515284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral transmucosal fentanyl citrate--OTFC (ACTIQ) #103.
    Gordon D; Schroeder M
    J Palliat Med; 2008 May; 11(4):633-4. PubMed ID: 18454617
    [No Abstract]   [Full Text] [Related]  

  • 15. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
    Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
    Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating cancer-related breakthrough pain: the oral transmucosal route.
    Laverty D
    Int J Palliat Nurs; 2007 Jul; 13(7):326-31. PubMed ID: 17851376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fentanyl nasal spray for the treatment of cancer pain.
    Mystakidou K; Panagiotou I; Gouliamos A
    Expert Opin Pharmacother; 2011 Jul; 12(10):1653-9. PubMed ID: 21609189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study.
    Hanks GW; Nugent M; Higgs CM; Busch MA;
    Palliat Med; 2004 Dec; 18(8):698-704. PubMed ID: 15623166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fentanyl effervescent buccal tablets: new formulation. For cancer patients with breakthrough pain: a second buccal formulation with minimal evaluation.
    Prescrire Int; 2009 Oct; 18(103):205. PubMed ID: 19882786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral trasmucosal fentanyl citrate for breakthrough pain treatment in cancer patients.
    Mercadante S
    Expert Opin Pharmacother; 2012 Apr; 13(6):873-8. PubMed ID: 22424558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.